For dates of service beginning July 1, 2014, Harvard Pilgrim will cover medically necessary stereotactic body radiation therapy (SBRT) when performed for the following diagnoses:
- 185 — malignant neoplasm of the prostate
- 233.4 — cancer in situ prostate
Harvard Pilgrim expanded coverage after receiving an increasing number of requests from providers for coverage of SBRT for these conditions and evaluating the clinical literature. For more information, please refer to the updated Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Medical Policy.